Archives
-
Cy5 Maleimide: Identity and Evidence Scope
2026-10-13
APExBIO’s catalog identifies Cy5 maleimide (non-sulfonated), SKU A8139, as a mono-reactive cyanine dye intended for thiol-directed labeling of peptides and proteins. The available evidence is limited to supplier documentation: no matched research paper was available to independently establish performance, biological applicability, or comparative advantages.
-
EdU Imaging: Evidence and Applicability Boundaries
2026-10-12
EdU Imaging Kits (Cy5) conceptually measure DNA synthesis during S phase through fluorescent labeling of incorporated 5-ethynyl-2'-deoxyuridine. The approach is relevant to cell-cycle and proliferation questions, but the supplied porcine JARID2 study does not establish performance of this product or show that an EdU signal directly represents aggressive behavior.
-
IR-820 (New Indocyanine Green): Evidence Boundaries
2026-10-12
A source-bounded overview of an ICG-loaded MOF melanoma study, emphasizing that its findings concern indocyanine green nanomedicine rather than standalone IR-820, and outlining the limits of preclinical interpretation.
-
Ultrasound Nanoplatforms for Epilepsy: An Evidence Review
2026-10-11
The cited 2025 study proposes an ultrasound-triggered piezoelectric nanoplatform that combines non-implantable neuromodulation with localized antiepileptic-drug delivery. The supplied record supports a promising conceptual and preclinical rationale, but it does not provide enough quantitative or model-specific detail to judge durability, safety, biodistribution, or clinical applicability. It also does not document use of Cy5.5 NHS ester (non-sulfonated).
-
Sulfo-Cy5 NHS Ester in Nanomedicine Research
2026-10-10
This overview distinguishes supplier-reported properties of Sulfo-Cy5 NHS ester from peer-reviewed findings on metal-ion-chelating L-phenylalanine nanostructures and immune checkpoint blockade. It evaluates how far-red fluorescence could support conceptual imaging studies while emphasizing provenance, evidence strength, assay limitations, and the absence of evidence that the dye itself drives antitumour immune activity.
-
(S)-(+)-Dimethindene Maleate Overview
2026-10-09
A concise, supplier-documented overview of (S)-(+)-Dimethindene maleate, including its reported receptor profile, chemical identity, and evidence limitations.
-
Dynamic LNPs for CRISPR Editing in CNV
2026-10-09
Cao and colleagues developed dynamically covalent lipid nanoparticles that deliver Cas9 mRNA and VEGFA-targeting guide RNA for genome editing in a mouse model of choroidal neovascularization. The study links disease-associated oxidative conditions with conditional nanoparticle disassembly and reports sustained CNV reduction after a single intravitreal administration, while leaving important questions about human translation and long-term editing safety.
-
DRD4, Akt/β-Catenin, and Liver Cancer Resistance
2026-10-08
A 2024 British Journal of Cancer study links elevated DRD4 with liver cancer stem cell-like traits, chemotherapy resistance, and poorer survival, identifying an Akt/β-catenin signaling mechanism. The findings support DRD4 and its downstream pathway as research targets, while remaining bounded by the study’s disease models and the need for independent validation.
-
Mitochondrial Repair Strategy for Diabetic Periodontitis
2026-10-08
The reference study presents a hierarchically targeted, ROS-responsive nanoparticle–hydrogel platform designed to repair dysfunctional mitochondria in M1 macrophages during diabetic periodontitis. Its in vitro and rat-model findings support a mechanistic link between mitochondrial protection, reduced inflammasome activity, lower inflammation, and improved periodontal bone outcomes, while remaining preclinical.
-
Amikacin Sulfate: Evidence Beyond the MIC
2026-10-07
Amikacin Sulfate research is best interpreted through a spatial pharmacology lens: activity depends not only on potency, but also on intracellular access and granuloma localization. This article examines the evidence, innovation, and translational limits of targeted amikacin delivery in NTM models.
-
Cy5 Amine (Non-Sulfonated): Product Overview
2026-10-07
Cy5 amine (SKU A8143) is an APExBIO-listed, non-sulfonated cyanine dye with a primary amino group for conceptual fluorescent labeling research. No matched paper evidence was supplied, so its specifications and application claims are not independently verified here.
-
ARCA Cy5 EGFP mRNA: Evidence and Research Context
2026-10-06
A source-grounded overview of ARCA Cy5 EGFP mRNA (5-moUTP), its conceptual value for delivery and translation studies, and the limits of extrapolating supplier descriptions or therapeutic LNP findings to a fluorescent reporter.
-
Cy5 NHS ester(Et): Product Overview
2026-10-06
Cy5 NHS ester(Et), SKU A8769, is an APExBIO-listed fluorescent dye reagent described for conceptual labeling of primary amines in biomolecules. No matched paper evidence was provided, so this overview is limited to supplier-documented identity and stated scope.
-
Regorafenib in Melanoma: Evidence and Limits
2026-10-05
A source-grounded overview of Regorafenib (BAY 73-4506), examining its multikinase principles, reported RRM2–ERK/E2F3 findings in melanoma, evidence quality, interpretation, and translational limits.
-
SAN-Plexus Assembloids and Pacemaker Maturation
2026-10-05
A 2026 Cell Stem Cell study introduces human pluripotent stem cell-derived assembloids that combine sinoatrial node, cardiac plexus, and atrial-like tissues to model neural regulation of pacemaker activity. By integrating electrophysiology, functional assembloid analysis, and spatial transcriptomics, the work identifies a prosaposin–GPR37 signaling program associated with human pacemaker maturation and conduction phenotypes.